AbbVie Reports Second-Quarter 2023 Financial Results

Reports Second-Quarter Diluted EPS of $1.14 on a GAAP Basis, an Increase of 123.5 Percent; Adjusted Diluted EPS of $2.91, a Decrease of 13.6 Percent; These Results Include an Unfavorable Impact of...

Related Keywords

United Kingdom ,British ,Lumigan Ganfort ,Alphagan Combigan ,Richarda Gonzalez ,Linzess Constella ,Epkinly Tepkinly ,Facebook ,Committee For Medicinal Products Human Use ,Roche Group ,Exchange Commission ,European Hematology Association ,European Congress ,Twitter ,Boehringer Ingelheim ,European Medicines Agency ,European Union ,Scripps Research ,Abbvie Inc ,Instagram ,Genentech ,Drug Administration ,Allergan ,Reports Second Quarter Diluted ,Adjusted Diluted ,These Results Include ,Unfavorable Impact ,Share Related ,Milestones Expense ,Second Quarter Net Revenues ,Reported Basis ,Quarter Global Net Revenues ,Immunology Portfolio Were ,Operational Basis ,Global Humira Net Revenues Were ,Global Skyrizi Net Revenues Were ,Global Rinvoq Net Revenues Were ,Hematologic Oncology Portfolio Were ,Global Imbruvica Net Revenues Were ,Global Venclexta Net Revenues Were ,Neuroscience Portfolio Were ,Global Botox Therapeutic Net Revenues Were ,Global Vraylar Net Revenues Were ,Aesthetics Portfolio Were ,Global Botox Cosmetic Net Revenues Were ,Global Juvederm Net Revenues Were ,Milestones Expense Incurred Year To Date Through ,Second Quarter ,Botox Therapeutic ,Botox Cosmetic ,Adapted Mayo Score ,British Journal ,Disease Week ,Annual Meeting ,Medicinal Products ,Human Use ,Annual Congress ,Allergan Aesthetics ,Investor Relations ,Private Securities Litigation Reform Act ,Quarterly Reports ,Ended June ,Months Ended June ,